Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support BB/statin continuation in OLT with CAD; leaves open confirmation in randomized trials.
In patients that undergo Orthotopic Liver Transplantation (OLT), the presence of Coronary Artery Disease (CAD) is associated with worse short-and long-term outcomes. With reported 3-year mortality rates up to 50%, recent efforts have focused on ways to reduce perioperative cardiovascular risk in this population. While continuation of Beta-Blocker (BB) and statin therapy has been shown to benefit patients with known CAD undergoing intermediate or high-risk noncardiac surgery, it is unknown whether these therapies benefit patients with CAD undergoing OLT.
No takes yet. Share an insight, caveat, or question.
Scott Lilly (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: